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Abstract
Background: Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of
sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child
transmission (MTCT) risk. We explored factors associated with HSV-2 seropositivity among HIV-positive women in
Ukraine, and its impact on HIV MTCT.
Methods: Data on 1513 HIV-positive women enrolled in the Ukraine European Collaborative Study from 2007 to
2012 were analysed. Poisson and logistic regression models respectively were fit to investigate factors associated
with HSV-2 seropositivity and HIV MTCT.
Results: Median maternal age was 27 years (IQR 24–31), 53 % (796/1513) had been diagnosed with HIV during their
most recent pregnancy and 20 % had a history of injecting drugs. Median antenatal CD4 count was 430 cells/mm3
(IQR 290–580). Ninety-six percent had received antiretroviral therapy antenatally. HSV-2 seroprevalence was 68 %
(1026/1513). In adjusted analyses, factors associated with HSV-2 antibodies were history of pregnancy termination
(APR 1.30 (95 % CI 1.18–1.43) for ≥2 vs. 0), having an HIV-positive partner (APR 1.15 (95 % CI 1.05–1.26) vs partner’s
HIV status unknown) and HCV seropositivity (APR 1.23 (95 % CI 1.13–1.35)). The overall HIV MTCT rate was 2.80 %
(95 % CI 1.98–3.84); no increased HIV MTCT risk was detected among HSV-2 seropositive women after adjusting for
known risk factors (AOR 1.43 (95 % CI 0.54–3.77).
Conclusion: No increased risk of HIV MTCT was detected among the 68 % of HIV-positive women with
antibodies to HSV-2, in this population with an overall HIV MTCT rate of 2.8 %. Markers of ongoing sexual risk
among HIV-positive HSV-2 seronegative women indicate the importance of interventions to prevent primary
HSV-2 infection during pregnancy in this high-risk group.
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In Ukraine HIV prevalence among pregnant women
was 0.8–1.0 % between 2009 and 2013, and over 3500
HIV-positive pregnant women gave birth in 2013 [1].
Initially injecting drug use drove the HIV epidemic in
Eastern Europe [2] but the main mode of acquisition
shifted to heterosexual transmission in 2008 [1] and
45 % of new HIV infections in 2013 were in women.
After the collapse of the Soviet Union, social changes
and poor public health provision resulted in an epi-
demic of sexually transmitted infections (STIs), par-
ticularly syphilis. Although syphilis rates subsequently
declined, rates of other STIs remain higher in Eastern
than Western Europe [3]; in a study of pregnant HIV-
positive women delivering in 1999–2005, those in
Ukraine had a 10-fold higher probability of having
syphilis, chlamydia or Trichomonas vaginalis than
their counterparts in Western Europe [4].
Prevalence of Herpes simplex virus Type 2 (HSV-2)
infection, the leading cause of genital ulcer disease
worldwide, is around 17–22 % in adults across Europe
and the United States with higher prevalence in HIV-
positive individuals (35–40 %) [5]. It is well established
that genital ulcer disease caused by HSV-2 increases
risk of HIV sexual acquisition [6]. During latency
HSV-2 is able to avoid clearance by the immune sys-
tem, but laboratory tests show specific antibodies and
it can cause recurrent activations, which are more
common and of longer duration with HIV co-infection
[7, 8]. This synergistic relationship between HIV and
HSV-2 also results in more frequent subclinical epi-
sodes of HSV-2 reactivation in HIV-positive individ-
uals, which seems to be associated with increases in
plasma and genital tract HIV viral load [9].
Mother-to-child-transmission (MTCT) rates of
HIV around 0.5 % have now been reported from
Western Europe [10, 11]. In Ukraine, the prevention of
MTCT (PMTCT) programme has achieved considerable
success, with MTCT rates reduced from 15 % in 2001 to
7 % in 2007 and around 4 % in 2010, following introduc-
tion of WHO Option B from 2007 [12, 13] (i.e. combined
antiretroviral therapy for all HIV-positive pregnant
women). Recent national reporting from Ukraine indi-
cated a MTCT rate of 4.3 % in 2012 [1]. Some data sug-
gest an increased risk of HIV MTCT for HSV-2/HIV co-
infected women in general [14] or with genital ulcers [15]
and a several trials showed decreased HIV RNA levels in
plasma or breastmilk after treatment with Valacyclovir
[16, 17].
Our primary aim was to investigate the influence
of HSV-2 co-infection on HIV MTCT risk in
Ukraine. Secondary aims were to describe the preva-
lence of HSV-2 antibodies among HIV-infected
childbearing women and associated risk factors.
Methods
Study setting and subjects
The European Collaborative Study (ECS) is a consented
cohort study of HIV-positive pregnant women and their
infants, which has enrolled women at regional HIV/AIDS
centres in Ukraine since 2000. Women diagnosed with
HIV before or during pregnancy or intrapartum and de-
livering a live-born infant are eligible. Linked anonymous
data on maternal, delivery and infant characteristics are
collected on standard questionnaires [13]. Between 2007
and 2012, HIV-positive women were enrolled at five cen-
tres (Odessa, Kyiv, Donetsk, Mykolaiv and Krivoy Rog)
into a nested postnatal sub-study, normally within 3–6
months of delivery, with the aim of obtaining longitu-
dinal information following delivery. Postnatal women
self-reported information on socio-demographic charac-
teristics and health behaviours (including drug use, access
to contraception and HIV status of current partner)
while clinicians provided clinical information [18]. Ethical
approval has been obtained from the Great Ormond
Street Hospital for Children NHS Trust/Institute of Child
Health Research Ethics Committee (reference 96EB02).
We obtained also local approvals from all the participat-
ing HIV/AIDS Centres.
The study population for this analysis was 1513
women and their infants enrolled in the Ukraine ECS
since 2007, with linked data from the postnatal cohort
on maternal HSV-2 serostatus.
Definitions
Injecting drug use (IDU) history was defined as self-
report, clinician’s assessment, or neonatal abstinence
syndrome in the infant. We used a threshold of HIV
RNA <75 copies/ml to define a viral load (VL) as
undetectable.
Infants with at least one positive virological marker
of infection at any age and/or persistence of anti-
bodies beyond 18 months of age were considered to
be HIV-positive, while infants with a negative PCR
test result for HIV DNA or RNA and/or negative
HIV antibody test were classified as HIV-negative,
regardless of age (excluding negative PCR test results
on the day of delivery). Infants with conflicting re-
sults or without data available were categorised as
having an indeterminate HIV status. For multiple
births, data on MTCT were based on the first-born
infant only unless infection status was discordant be-
tween twins/triplets, in which case the infected in-
fant was retained.
Combined antiretroviral therapy (cART) was defined
as ≥3 antiretroviral drugs taken simultaneously; 12
women receiving antenatal dual therapy were included
in the monotherapy group throughout. Elective caesarean
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section was defined as before rupture of membranes and
onset of labour.
Data analysis
Univariable comparisons were assessed with the chi-square
test or Fisher’s exact test for categorical variables and the
Wilcoxon rank sum test for continuous variables. Poisson
regression models with robust variance estimators were fit-
ted to obtain prevalence ratios (PR) and adjusted prevalence
ratios (aPR) and 95 % confidence intervals (CI) in analyses
investigating factors associated with positive HSV-2 serosta-
tus. Socio-demographic characteristics and co-infections as-
sociated with HSV-2 seropositivity in univariable analyses
(p <0.1) were included in the multivariable model, with the
exception of those which were considered likely to have
post-dated HSV-2 seroconversion.
Logistic regression models fitted to investigate the im-
pact of HSV-2 seropositivity on risk of HIV MTCT were
adjusted a priori for factors previously found to be associ-
ated with HIV MTCT in this cohort (use of antenatal
ART, mode of delivery, preterm delivery and IDU history)
[13] and time period of delivery (2007–09 vs 2010–12)
and centre, which was included as a random effect to ac-
count for regional differences in clinical practice and in
maternal characteristics. Sub-analyses were conducted to
explore the association between HSV-2 seropositivity and
HIV MTCT among (a) mother-child pairs with maternal
syphilis serology, as positive syphilis serology has previ-
ously been associated with HIV MTCT risk in this popu-
lation [19]; (b) women who delivered vaginally; (c) women
who did not receive antenatal cART.
Statistical analysis was performed using STATA ver-
sion 12 (Stata Corp LP, College Station USA).
Results
The 1513 HIV-positive women with HSV-2 serostatus
available were enrolled into the postnatal cohort a me-
dian of 3.9 months (interquartile range (IQR) 1.1–10.3)
after delivery. Median maternal age was 27.3 years (IQR
24.1–30.8) and 87 % (1306/1509) were married or co-
habiting. Just under half (647/1423) were primiparous,
and 53 % (796/1513) had been diagnosed as HIV-
infected during their most recent pregnancy, with 143
(9 %) diagnosed in the third trimester or during delivery.
A fifth (295/1504) of women had an IDU history and a
similar proportion (286/1464) had a sexual partner who
injected drugs.
Median antenatal CD4 count measurement was 430
cells/mm3 (IQR 290–580), measured at median 21.3 weeks
gestation (IQR 15.6–26.7); 36 % (414/1165) had a CD4
count ≤350 cells/mm3 and 15 % (204/1321) had WHO
Stage 3 or 4 HIV disease. Almost all (96 %, 1451/1509) re-
ceived antenatal ART but most discontinued this at deliv-
ery, with only a quarter (410/1498) still on treatment at
postnatal cohort enrolment. Only 53 % (800/1513) of
women had an antenatal HIV RNA measurement; 373
women had a measurement available within 90 days (me-
dian 37 days) before delivery and while on ART, of whom
42 % (158) were virologically suppressed after a median of
9.7 weeks (IQR 5.3–13.4) on treatment.
HSV-2 seroprevalence was 68 % (1026/1513); for 87 %
(1309/1509), the HSV-2 antibody test was conducted
during pregnancy, for 6 % (88/1509) prior to conception
and 7 % (112/1509) after delivery. Table 1 presents mater-
nal and delivery characteristics stratified by HSV-2
serostatus.
Factors associated with positive HSV-2 seropositivity
The proportion of women with HSV-2 antibodies in-
creased significantly with age, from 57 % of women aged
16–23 years to 71 % of those aged >30 years, with higher
parity and history of pregnancy termination also associ-
ated with increased probability of positive HSV-2 seros-
tatus (Table 1). With respect to other STIs, 1.9 % (9/
481) of HSV-2 seronegative women and 2.0 % (20/981)
of HSV-2 seropositive women had positive serology for
syphilis (Fisher’s exact test p = 1.0), 10.6 % (43/405) and
31 % (158/511) respectively had a positive chlamydia test
(χ2 = 54.37, p <0.01) and 0.5 % (2/430) and 0.3 % (2/759)
respectively for gonorrhoea (Fisher’s exact test p = 0.62).
Women with HSV-2 antibodies were more likely to have
a history of IDU, be positive for HCV antibodies and
HBsAg, and report an HIV-positive partner (Table 1).
HSV-2 seropositive women were more likely to report
their most recent pregnancy as having been unplanned
(Table 1, p = 0.06), but reported better access to family
planning than HSV-2 seronegative women at cohort en-
rolment (Table 1).
A greater proportion of women with HSV-2 antibodies
had been diagnosed with HIV before conception (Table 1)
and 8 % (81/973) conceived on ART compared with 4 %
(18/466) of seronegative women (χ2 = 9.79, p <0.01).
Among those initiating ART during pregnancy, HSV-2
seropositive women were more likely to receive cART
than seronegative women (51 % (451/892) vs. 37 % (165/
448) respectively, χ2 = 22.64, p <0.01) and a slightly higher
proportion had a pre-ART CD4 count of ≤350 cells/mm3
(38 % (249/649 vs. 32 % (56/176), χ2 = 2.55, p = 0.11). Of
455 women who had a viral load measure before ART
start (373 (82 %) of whom were HSV-2 seropositive),
median viral load was 11369 copies/ml (IQR 2392, 38676),
with no difference by HSV-2 serostatus (Wilcoxon rank
sum test p = 0.76). Overall 16 % (154/934) of HSV-2
seropositive women had WHO stage 3 or 4 disease com-
pared with 13 % (50/387) of HSV-2 seronegative women
(χ2 = 2.67, p = 0.10).
The multivariable model exploring factors associated
with HSV-2 seropositivity excluded access to family
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χ2 value and p value
Maternal age (n = 1512) χ2 = 20.34 p <0.001
16–23 years 116 (24) 155 (15)
24–26 years 148 (30) 302 (29)
27–30 years 119 (24) 319 (31)
31 years 104 (21) 249 (24)
Marital status (n = 1509) χ2 = 0.82 p = 0.364
Married/cohabiting 415 (85) 891 (87)
Single/divorced/widowed 71 (15) 132 (13)
Age at leaving full-time education (n = 1088) χ2 = 4.39 p = 0.111
≤16 years 53 (21) 222 (27)
17–18 years 65 (26) 230 (27)
≥19 years 133 (53) 385 (46)
Parity (n = 1423) χ2 = 16.70 p <0.001
0 245 (53) 402 (42)
1 165 (36) 392 (41)
≥2 54 (12) 165 (17)
Previous pregnancy terminations (n = 1398) χ2 = 63.35 p <0.001
0 280 (62) 373 (40)
1 79 (17) 214 (23)
≥2 95 (21) 357 (38)
Pregnancy planned (n = 1501) χ2 = 3.44 p = 0.064
No 130 (27) 320 (31)
Yes 355 (73) 696 (69)
Has access to family planning (n = 1087) χ2 = 28.02 p <0.001
No 75 (16) 39 (6)
Yes 388 (84) 585 (94)
Timing of HIV diagnosis (n = 1513), χ2 = 6.06 p = 0.109
Before pregnancy 167 (34) 407 (40)
First or second trimester 264 (54) 532 (52)
Third trimester/delivery 56 (12) 87 (8)
History of IDU (n = 1504) χ2 = 6.48 p = 0.011
No 409 (84) 800 (79)
Yes 77 (16) 218 (21)
Partner’s HIV statusa (n = 1352) χ2 = 36.95 p <0.001
Unknown 137 (32) 238 (26)
Negative 144 (34) 210 (23)
Positive 146 (34) 477 (52)
HCV serostatus (n = 1402) χ2 = 46.82 p <0.001
Negative 344 (79) 589 (61)
Positive 89 (21) 380 (39)
Hepatitis B surface antigen (n = 1451) χ2 = 18.89 p <0.001
Negative 409 (87) 756 (77)
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planning, because the higher levels of access reported by
HSV-2 seropositive women may have been due to
treatment-seeking for symptomatic STIs (including geni-
tal ulcer disease) or termination of pregnancy and there-
fore may post-date HSV-2 seroconversion. Chlamydia
was also excluded because, as an often transient bacterial
infection, it is likely to have been acquired in the period im-
mediately preceding testing and after chronic HSV-2 infec-
tion. In the final adjusted model, women with a history of
pregnancy termination (vs no history), who reported their
partner to be HIV-positive (vs of unknown HIV status) and
who had HCV antibodies remained at increased risk of
HSV-2 seropositivity (Table 2).
Although IDU history was associated with HSV-2 sero-
positivity among 1402 women in univariable analysis, this
association was not apparent among the 1095 women in-
cluded in the adjusted model (Table 2), indicating some
bias in the complete-case analysis. However, among 1394
women with both IDU history and HCV serostatus avail-
able, the association between HSV-2 antibodies and HCV
seropositivity after adjusting for IDU history remained
(APR 1.31 95 % CI 1.21–1.42) with no association between
HSV-2 antibodies and IDU after adjusting for HCV anti-
bodies (APR 0.95 95 % CI 0.86–1.03), indicating that the
observed association between HCV and HSV-2 seropositiv-
ity was not explained by factors specific to IDUs (e.g. sexual
risk behaviours). Of note, 22 % (249/1119) of women with-
out an IDU history in this population had HCV antibodies
vs 79 % (217/275) of those with an IDU history.
Infants and MTCT
Delivery and infant data are presented in Table 3. Infants
of HSV-2 seropositive mothers were more likely to be
delivered vaginally and to be of low birthweight than
other infants (Table 3). Almost all (99.4 %, 1497/1506)
infants were exclusively formula fed. At the time of ana-
lyses, all children were at least 2 years of age (median
4.98 years, IQR 3.76–6.26) and DNA PCR test results
were available for 80 % (1216/1513). HIV status was
available for 89 and 83 % of infants of HSV-2 seroposi-
tive and -negative women respectively (χ2 = 11.86, p
<0.01); 37 infants were HIV-infected, giving an overall
HIV MTCT rate of 2.8 % (95 % CI 1.98–3.84) (Table 3).
There was no evidence that HSV-2 seropositivity was as-
sociated with HIV MTCT risk in unadjusted analyses
(Tables 3 and 4, HIV MTCT rate was 3.2 % among
HSV-2 seronegative women and 2.6 % among HSV-2
seropositive women, χ2 = 0.37, p = 0.54).
In multivariable analyses, the only factor associated
with HIV MTCT was lack of antenatal ART, associated
with a three-fold increased risk (Table 4). In the first of
the three sub-analyses of factors associated with HIV
MTCT risk, adjusting additionally for maternal syphilis
serology among 1241 mother-child pairs with this avail-
able, the AOR for positive versus negative HSV-2 seros-
tatus was 1.39 (95 % CI 0.51–3.80, p = 0.523). In the
sub-analysis restricted to the 927 women delivering vagi-
nally the AOR for HSV-2 seropositive vs seronegative
was 1.46 (95 % CI 0.40–5.34 p = 0.565) and in the sub-
analysis restricted to 629 women without antenatal
cART, the AOR was also not significantly increased
(AOR 1.57, 95 % CI 0.30–8.12, p = 0.590).
Discussion
In this large cohort of HIV-positive pregnant women, we
found that two-thirds had antibodies to HSV-2. Almost
all women received antenatal ART and around half re-
ceived cART; the HIV MTCT rate was 2.8 % overall,
with no increased risk of MTCT of HIV detected among
HSV-2 seropositive women.
Recent global estimates of prevalent HSV-2 in adults
aged 15–49 years in 2012 indicated prevalence in fe-
males of 14.8 % and in males of 8.0 %; in Europe the es-
timate was 10 % for women and 4 % for men [20]. High
HSV-2 prevalence is reported in women living with HIV,
for example, 86 % of HIV-positive pregnant women in a
Nairobi study [21]. In a Canadian study of Africa/Carib-
bean-born women, prevalence of HSV-2 infection was
86 % in HIV-positive and 47 % in HIV-negative women
[22]. Thus our finding of a seroprevalence of 68 % is
consistent with published estimates.
HSV-2 is a persistent infection and thus prevalence in-
creases with age, as seen here and demonstrated else-
where. In the global estimates study, prevalence increased
from <5 % in 15–19 year olds, to 13 % by age 30–34 and
17 % by age 45–49 [20]. In our adjusted analyses we found
that HSV-2 seropositive women were more likely to have
a history of pregnancy termination, which may be a
marker of greater sexual risk, including lack of or incon-
sistent use of barrier contraception. In this population,
Table 1 Maternal socio-demographic and clinical characteristics, stratified by HSV-2 status (Continued)
Positive 62 (13) 224 (23)
Antenatal/intrapartum antiretrovirals (n = 1508) χ2 = 31.42 p <0.001
cART 183 (38) 542 (53)
ZDV +/− sdNVP 283 (58) 443 (43)
None or sdNVP only 19 (4) 38 (4)
a As reported by the woman
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condoms are the main form of contraception [23] which
is an ineffective family planning method and of only mod-
erate effectiveness in preventing acquisition of HSV-2
[24]. Other factors associated with significantly greater
probability of HSV-2 seropositivity were having a known
HIV-positive partner and being co-infected with HCV.
The epidemiology of HCV infection in Ukraine is not well
understood with over a fifth of non-IDUs in this cohort
reported to be HCV seropositive. HCV is more sexually
transmissible among HIV-positive individuals [25] and
our findings of an association between HCV and HSV-2
seropositivity may indicate shared risk factors for sexual
acquisition. However, risk factors for HCV acquisition in
this setting may also include iatrogenic exposures, which
could have been more common among HSV-2 seropositive
women given their greater likelihood of history of preg-
nancy termination.
We did not detect an association between HSV-2 anti-
bodies and increased risk of HIV MTCT; this is in contrast
with findings from other studies, which reported an associ-
ation between HSV-2 antibodies or genital ulcer disease
and HIV MTCT [15, 16, 26, 27]. These studies were all
conducted more than 10 years ago in populations with
much higher background rates of HIV MTCT. Our sample
size of 404 HSV-2 seronegative and 916 seropositive
mothers and 3.2 % transmission rate in the seronegative
group allowed us to rule out a 2.25-fold increased risk of
HIV MTCT with HSV-2 antibodies (i.e. a transmission rate
Table 2 Factors associated with a maternal positive HSV-2 serostatus
Proportion of women
with HSV-2 antibodies




16–23 years 57 % (155/271) 1.00 1.00
24–26 years 67 % (302/450) 1.19 (1.04–1.37) 0.014 1.11 (0.97–1.28) 0.137
27–30 years 73 % (319/438) 1.25 (1.09–1.44) 0.002 1.09 (0.95–1.26) 0.218
≥31 years 71 % (249/353) 1.23 (1.07–1.43) 0.004 1.03 (0.88–1.21) 0.676
Parity
0 62 % (402/647) 1.00 1.00
1 70 % (392/557) 1.13 (1.03–1.23) 0.009 1.01 (0.91–1.10) 0.913
≥2 75 % (165/219) 1.14 (1.01–1.28) 0.027 0.99 (0.87–1.12) 0.857
History of pregnancy
termination
0 57 % (373/653) 1.00 1.00
1 73 % (214/293) 1.24 (1.11–1.38) <0.001 1.22 (1.10–1.36) <0.001
≥2 79 % (357/452) 1.36 (1.25–1.49) <0.001 1.30 (1.18–1.43) <0.001
Pregnancy planned
No 71 % (320/450) 1.00 1.00
Yes 66 % (696/1051) 0.96 (0.88–1.05) 0.343 1.03 (0.94–1.13)
History of IDU
No 66 % (800/1209) 1.00 1.00
Yes 74 % (218/295) 1.05 (0.96–1.16) 0.299 0.93 (0.83–1.03) 0.174
Partner’s HIV statusa
Unknown 63 % (238/375) 1.00 1.00
Negative 59 % (210/354) 0.90 (0.79–1.04) 0.147 0.91 (0.79–1.05) 0.184
Positive 77 % (477/623) 1.21 (1.10–1.33) <0.001 1.15 (1.05–1.26) 0.003
HCV serostatus
Negative 63 % (589/933) 1.00 1.00
Positive 81 % (380/469) 1.25 (1.16–1.35) <0.001 1.23 (1.13–1.35) <0.001
Hepatitis B surface
antigen
Negative 65 % (756/1165) 1.00 1.00
Positive 78 % (224/286) 1.20 (1.11–1.31) <0.001 1.06 (0.97–1.16) 0.179
a As reported by the woman
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of ≥7.2 %), with 80 % power and alpha 0.05. To have de-
tected a 50 % increased risk, as previously reported in the
Zimbabwean study [27], would have required a much larger
sample size of around 1850 HSV-2 seronegative and 4200
HSV-2 seropositive women, given the low HIV MTCT rate
overall. Therefore, although we did not detect an associ-
ation between HSV-2 antibodies and increased risk of HIV
MTCT, our study did not have sufficient statistical power
to rule out the smaller increases in HIV MTCT risk associ-
ated with HSV-2 seropositivity found previously, due to the
low HIV MTCT rates overall in our study population, al-
most all of whom received antenatal ART.
Although we showed a significant association be-
tween MTCT and use of ART, we were unable to ex-
plore the association between HSV-2 serostatus and
MTCT after adjusting for maternal HIV viral load be-
cause of limited viral load testing: of the 37 HIV-
infected infants, 23 were born to women with no
antenatal HIV RNA measure available and only five
mothers of the remaining 14 had a measurement
available in the 90 days preceding delivery. The HIV
MTCT rate reported here was substantially lower
than that observed in the Ukraine ECS overall in the
same time period (4.56 %, 95 % CI 4.04–5.13), be-
cause our analysis was restricted to a postnatal cohort
who generally had better access to PMTCT interven-
tions, reflecting greater engagement with antenatal
and HIV care services [13].
The high prevalence of HSV-2 found in our HIV-
positive pregnant women has implications for their in-
fants. Neonatal HSV-2 infection is a serious condition
associated with high morbidity and mortality, with anti-
viral prophylaxis for HSV-2 recommended during preg-
nancy in women with frequent clinical recurrences. In
HIV co-infected women this could have the additional
benefit of reducing HIV viral load and/or HIV MTCT
risk. However, risk of vertical transmission of HSV-2 is
higher in primary infection during pregnancy (around
40 %) compared to recurrent infections (1–3 %) [28].
PCR test results and data on clinical symptoms were
not available, and we were therefore unable to make
conclusions about the timing of HSV-2 seroconversions
here or prevalence of genital ulcer disease during preg-
nancy, however most HSV-2 seropositive women had
been tested during pregnancy (87 %) or pre-conception
(6 %). Of HSV-2 seronegative women, 1 in 10 had a re-
cent chlamydia diagnosis, indicating ongoing sexual risk
and potential risk of HSV-2 acquisition during preg-
nancy. Up to 20 % of HSV-2 seronegative women with
an HSV-2-infected partner will seroconvert during preg-
nancy, with highest risk of neonatal infection if this oc-
curs late in pregnancy [29]. Some experts suggest
partner testing of pregnant women susceptible to HSV-
2 and counselling of those with a positive partner about
abstinence and reducing oral-genital contact near term
[30].
As the postnatal cohort enrols women retained in
HIV care following delivery, our study population may
have had better uptake of sexual and reproductive
health services. Our results may therefore not be
generalizable to the entire HIV-positive childbearing
population in Ukraine; in reality, HSV-2 seroprevalence
Table 3 Delivery and infant characteristics, stratified by maternal HSV-2 serostatus
HSV-2 seronegative n (%) HSV-2 seropositive n (%) χ2 value and p value
Total live births 487 1026 –
Mode of delivery (n = 1483) χ2 = 73.17 p <0.001
Vaginal 277 (58) 784 (78)
Elective CS 180 (38) 176 (18)
Emergency CS 20 (4) 46 (5)
Gestational age (n = 1505) χ2 = 0.45 p = 0.501
≥37 completed weeks 445 (92) 928 (91)
<37 completed weeks 39 (8) 93 (9)
Birth weight (n = 1508)
≥2500 g 441 (91) 890 (87) χ2 = 4.25 p = 0.039
<2500 g 45 (9) 132 (13)
HIV infection status (n = 1513) χ2 = 12.22 p <0.01
Infected 13 (2.67) 24 (2.34)
Uninfected 391 (80.29) 892 (86.94)
Indeterminate/unknown 83 (17.04) 110 (10.72)
MTCT rate (%) where infant 3.2 % (95 % CI 1.7–5.4) 2.6 % (95 % CI 1.7–3.9) χ2 = 0.37, p = 0.54
HIV status known (n = 1320)
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may be higher if women not engaged with services after
delivery were also more likely to have HSV-2 co-
infection. More research is needed on occurrence of
genital ulcer disease among HSV-2 seropositive women
and outcomes of their neonates, and more generally
about sexual health of women in Ukraine living with or
at high risk of acquiring HIV, to strengthen preventative
health services
Conclusion
In conclusion, we found a high prevalence of HSV-2 anti-
bodies but no associated increased risk of vertical HIV
transmission, in this population with an overall HIV
MTCT rate of 2.8 %. High prevalence of recent chlamydia
diagnosis indicated ongoing sexual risk, suggesting that
HSV-2 seronegative women may benefit from counselling
on prevention of HSV-2 acquisition during pregnancy and
that clinicians should be alert to the possibility of a pri-
mary maternal infection, while HSV-2 seropositive women
with clinical symptoms require appropriate obstetric
management.
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Table 4 Factors associated with MTCT of HIV
Number with MTCT (%) Odds ratio (95 % CI) Adjusted odds ratio (95 % CI),
p value n = 1286a
Length of gestation
≥37 completed weeks 33/1204 (2.7) 1 1
<37 completed weeks 4/109 (3.7) 0.73 (0.25–2.09) p = 0.553 0.93 (0.30–2.82) p = 0.891
Mode of delivery
Vaginal 27/942 (2.9) 1 1
Elective CS 9/305 (3.0) 1.03 (0.48–2.21) p = 0.945 0.76 (0.32–1.80) p = 0.529
Emergency CS 1/58 (1.7) 0.58 (0.08–4.38) p = 0.602 1.04 (0.13–8.28) p = 0.973
Antenatal/intrapartum ARVs
cART 11/607 (1.8) 1 1
ZDV +/− sdNVP 20/666 (3.0) 0.61 (0.29–1.28) p = 0.190 0.59 (0.27–1.31) p = 0.194
None or sdNVP only 6/42 (14.3) 5.31 (2.01–14.03) p <0.01 3.42 (1.19–9.85) p = 0.023
IDU history
No 30/1057 (2.8) 1 1
Yes 7/254 (2.8) 0.98 (0.43–2.26) p = 0.964 1.18 (0.46–2.99) p = 0.735
HSV-2 serostatus
Negative 13/404 (3.2) 1 1
Positive 24/916 (2.6) 0.80 (0.41–1.60) p = 0.553 1.43 (0.54–3.77) p = 0.474
a Adjusted additionally for time period of delivery (2007–09 vs. 2010–12) and including random effect term for centre of enrolment
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